Enoximone sulfoxide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 576981

CAS#: 83982-78-9

Description: Enoximone sulfoxide is a selective phosphodiesterase III (PDE3) inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. Enoximone prevents the degradation of cAMP by PDE, which prolongs signal transduction and its subsequent effects. It is used in patients with congestive heart failure.

Chemical Structure

img
Enoximone sulfoxide
CAS# 83982-78-9
Instruction

Theoretical Analysis

MedKoo Cat#: 576981
Name: Enoximone sulfoxide
CAS#: 83982-78-9
Chemical Formula: C12H12N2O3S
Exact Mass: 264.06
Molecular Weight: 264.300
Elemental Analysis: C, 54.53; H, 4.58; N, 10.60; O, 18.16; S, 12.13

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Enoximone sulfoxide; Mdl17043 sulfoxide; Mdl-17043 sulfoxide; Mdl 17043 sulfoxide

IUPAC/Chemical Name: 4-methyl-5-(4-(methylsulfinyl)benzoyl)-1,3-dihydro-2H-imidazol-2-one

InChi Key: XHRYEIRXTWSXAE-UHFFFAOYSA-N

InChi Code: InChI=1S/C12H12N2O3S/c1-7-10(14-12(16)13-7)11(15)8-3-5-9(6-4-8)18(2)17/h3-6H,1-2H3,(H2,13,14,16)

SMILES Code: CC1=C(NC(=O)N1)C(=O)c2ccc(cc2)S(=O)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 264.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Liu X, Qu X, Wu C, Zhai Z, Tian B, Li H, Ouyang Z, Xu X, Wang W, Fan Q, Tang T, Qin A, Dai K. The effect of enoxacin on osteoclastogenesis and reduction of titanium particle-induced osteolysis via suppression of JNK signaling pathway. Biomaterials. 2014 Jul;35(22):5721-30. doi: 10.1016/j.biomaterials.2014.04.006. Epub 2014 Apr 22. PubMed PMID: 24767789.

2: Rivera MF, Chukkapalli SS, Velsko IM, Lee JY, Bhattacharyya I, Dolce C, Toro EJ, Holliday LS, Kesavalu L. Bis-enoxacin blocks rat alveolar bone resorption from experimental periodontitis. PLoS One. 2014 Mar 17;9(3):e92119. doi: 10.1371/journal.pone.0092119. eCollection 2014. PubMed PMID: 24638087; PubMed Central PMCID: PMC3956892.

3: Sousa E, Graça I, Baptista T, Vieira FQ, Palmeira C, Henrique R, Jerónimo C. Enoxacin inhibits growth of prostate cancer cells and effectively restores microRNA processing. Epigenetics. 2013 May;8(5):548-58. doi: 10.4161/epi.24519. Epub 2013 Apr 17. PubMed PMID: 23644875; PubMed Central PMCID: PMC3741225.

4: Toro EJ, Zuo J, Ostrov DA, Catalfamo D, Bradaschia-Correa V, Arana-Chavez V, Caridad AR, Neubert JK, Wronski TJ, Wallet SM, Holliday LS. Enoxacin directly inhibits osteoclastogenesis without inducing apoptosis. J Biol Chem. 2012 May 18;287(21):17894-904. doi: 10.1074/jbc.M111.280511. Epub 2012 Apr 2. PubMed PMID: 22474295; PubMed Central PMCID: PMC3366803.

5: Toro EJ, Ostrov DA, Wronski TJ, Holliday LS. Rational identification of enoxacin as a novel V-ATPase-directed osteoclast inhibitor. Curr Protein Pept Sci. 2012 Mar;13(2):180-91. Review. PubMed PMID: 22044158; PubMed Central PMCID: PMC3409362.

6: Melo S, Villanueva A, Moutinho C, Davalos V, Spizzo R, Ivan C, Rossi S, Setien F, Casanovas O, Simo-Riudalbas L, Carmona J, Carrere J, Vidal A, Aytes A, Puertas S, Ropero S, Kalluri R, Croce CM, Calin GA, Esteller M. Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A. 2011 Mar 15;108(11):4394-9. doi: 10.1073/pnas.1014720108. Epub 2011 Feb 28. PubMed PMID: 21368194; PubMed Central PMCID: PMC3060242.